Featured Editorial

  1. MicroRNA Therapeutics In Metabolic Liver Disease: Context-Driven Drug Discovery 3/12/2026

    Realizing the therapeutic potential of miRNAs in liver disease requires confronting a problem the field has not fully reckoned with.

  2. Inside Alnylam's Playbook For High Volume siRNA Production 3/10/2026

    As one of the first companies to establish a chemoenzymatic ligation platform, Alnylam's Maines and Nechev are in the perfect position to espouse wisdom on the practical aspects and remaining challenges of implementing enzymatic ligation at a large scale. Here in this installment, Maines and Nechev outline what they’ve learned thus far about the science of enzymatic ligation, while also paying credence to the unknowns and existing barriers that, as a frontrunner, Alnylam will inevitably (but willingly) be tasked with facing in the future.

  3. Dual Centrifugation And The Next Phase Of Lipid Nanoparticle Development 3/9/2026

    Dual centrifugation enables rapid, small-scale LNP screening with high encapsulation, reproducibility, and preserved RNA integrity — offering a flexible bridge between benchtop discovery and scalable manufacturing.

  4. The FDA Plausible Mechanism Framework Just Changed Rare Disease Drug Development 3/9/2026

    Discover how the new FDA Plausible Mechanism Framework changes the game for rare disease research by formalizing an approval pathway for individualized treatment of ultra-rare genetic diseases.

  5. The Future Of Kidney Disease Therapeutics: Bringing Nanomedicine To Nephrology 3/6/2026

    Nanomedicines are solving the drug delivery problem in kidney disease. The next step: bridging the translational gap to advance these technologies into the clinic.

  6. Proteomics Tools: A Resurrection 3/4/2026

    For decades, the evolution of proteomics has lagged. Now, a resurrection is underway. New tools are dismantling limitations, signifying a maturation of systems biology.

  7. The "Middle Ground" Advantage: Why Alnylam Is Betting Big On Chemoenzymatic Ligation 3/3/2026

    Though conversations are picking up around this hybrid approach, we aren’t exactly known as an industry that embraces risk no-holds barred. While there are a handful of manufacturers and CDMOs who are embracing the hybrid model today, there are many more that are likely to hold out for the next-next gen approach: Fully enzymatic oligo production. However, as Alynlam’s CTO and Chief Quality Officer Tim Maines argued, embarking into the “middle ground” of enzymatic ligation is essential for garnering the step-by-step learnings needed to help us unlock even bigger manufacturing wins in the future. 

  8. Engineering Translation: How tRNA Therapeutics Expand The RNA Toolkit 3/3/2026

    Engineered tRNAs target translation itself — correcting shared errors like premature stop codons at the ribosome — to restore functional protein and redefine precision medicine by mechanism, not diagnosis.

  9. Microneedle Delivery Of Telomerase Protects Skin From Radiation-Induced DNA Damage 3/2/2026

    Pre-treatment with telomerase mRNA shields human skin from radiation-induced DNA damage, reducing radiotherapy side effects.

  10. The Evolution Of Oligonucleotide Manufacturing: Engineering Considerations For Scale, Efficiency, And Facility Design 2/27/2026

    As oligos move toward larger indications, manufacturing shifts from chemistry alone to facility design—balancing scale, solvent safety, cost, and flexibility as SPOS, slurry, and enzymatic paths converge.